Welcome to our dedicated page for ANTERIS TECHNOLOGIES GLOBAL SEC filings (Ticker: AVR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Anteris Technologies Global Corp. (AVR) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory documents, giving investors a detailed view of its structural heart business and capital markets activity. As a medical instruments and supplies company focused on the DurAVR Transcatheter Heart Valve (THV) System, Anteris uses its filings to describe its technology, clinical programs and financial profile.
Through registration statements such as the Form S‑1, readers can review the company’s business overview, including its description of DurAVR THV as a balloon‑expandable biomimetic aortic valve, the role of its proprietary ADAPT tissue technology and the design of the ComASUR balloon‑expandable delivery system. These filings also outline the PARADIGM Trial, a global prospective randomized controlled trial comparing DurAVR THV to commercially available TAVR devices, and explain how the trial is intended to support a future Premarket Approval application and CE Mark progress.
Current reports on Form 8‑K document material events such as FDA IDE approval for PARADIGM, first patient enrollment and treatment in the pivotal trial, clinical data presentations, capital raising transactions involving common stock, CHESS Depositary Interests and warrants, and other corporate developments. Definitive proxy statements on Schedule 14A provide detail on the annual meeting agenda, director elections, equity incentive awards and stockholder voting procedures.
On Stock Titan, these filings are updated in near real time from EDGAR and can be paired with AI‑generated summaries that highlight key points from lengthy documents. Users can quickly locate quarterly reports on Form 10‑Q, annual reports on Form 10‑K (when filed), 8‑K event disclosures and registration statements, and use AI‑assisted explanations to understand complex sections such as risk factors, clinical trial descriptions, capital structure and equity compensation proposals.
For those analyzing AVR, the filings page offers a structured way to follow how Anteris presents its structural heart strategy, clinical evidence plans and financing arrangements to regulators and investors.
Anteris Technologies Global Corp. reported an equity transaction by its Chief Operating Officer and director. On December 16, 2025, the reporting person acquired 166,666 shares of common stock through the vesting and settlement of restricted stock units, recorded as a code "M" transaction. On the same date, 65,584 shares were disposed of in a code "F" transaction at a price of $4.95 per share, typically reflecting shares withheld to cover taxes. After these transactions, the reporting person directly held 101,082 shares of common stock.
The derivative table shows this activity came from a grant of 500,000 restricted stock units awarded on December 16, 2024, which vest in approximately equal installments on December 16 of 2025, 2026, and 2027, subject to continued service. Following the reported transaction, 333,334 restricted stock units remained beneficially owned.
Anteris Technologies Global Corp. Chief Financial Officer Matthew McDonnell reported the vesting of a portion of his equity award and the related share issuance. On December 16, 2024, he was granted 83,333 restricted stock units (RSUs), scheduled to vest in approximately equal installments on December 16, 2025, 2026 and 2027, subject to his continued service. On December 16, 2025, 27,777 RSUs vested and converted on a one-for-one basis into common stock, recorded as an acquisition of 27,777 shares at a price of $0.
Following this transaction, McDonnell beneficially owns 27,777 common shares indirectly through Citicorp Nominees Pty Ltd and 55,556 RSUs directly, each RSU convertible into one share of common stock. The common stock received is represented as CHESS Depositary Interests traded on the Australian Securities Exchange.
Anteris Technologies Global Corp. chief executive officer and director Wayne Paterson reported equity award activity involving the company’s common stock. On December 16, 2025, a tranche of 333,333 restricted stock units (RSUs) converted on a one-for-one basis into the same number of common shares, reflecting previously granted equity compensation.
The filing also shows a disposition of 163,213 common shares at $4.95 per share, typically consistent with share sales to cover tax withholding on vested awards. After these transactions, Paterson held 182,727 common shares indirectly through Citibank, N.A. London as custodian and 20,334 shares directly, along with 666,667 RSUs that remain outstanding. These RSUs are part of a 1,000,000-unit grant awarded on December 16, 2024, vesting in roughly equal installments on December 16 of 2025, 2026, and 2027, which stockholders approved on December 3, 2025.
Anteris Technologies Global Corp. director John Seaberg reported the vesting and conversion of restricted stock units into common stock. On 12/16/2025, 27,777 restricted stock units were converted into 27,777 shares of common stock in a transaction coded "M," increasing his directly held common shares to 43,635. He also holds 3,852 shares indirectly through Citibank, N.A. London as custodian.
The derivative table shows these 27,777 restricted stock units converting at an exercise price of $0 into common stock, leaving 55,556 restricted stock units beneficially owned following the transaction. These units come from a contingent grant of 83,333 restricted stock units awarded on December 16, 2024, which vest in approximately equal installments on December 16, 2025, 2026 and 2027, subject to continued service and approval previously obtained from stockholders on December 3, 2025.
Anteris Technologies Global Corp. filed a prospectus supplement linked to its Form S-1 registration statement covering up to 9,103,796 shares of common stock that may be sold from time to time by selling stockholders. The supplement incorporates information from a newly filed Current Report on Form 8-K.
The attached 8-K notes that on December 13, 2025 (December 14, 2025 in Australia), Stephen Denaro resigned, with immediate effect, from the Company’s Board of Directors as a Class II director, and his resignation was not due to any disagreement over operations, policies or practices. He will continue as corporate secretary of Anteris Technologies Pty Ltd and as a director of that and other Australian subsidiaries. The Company’s common stock trades on Nasdaq under the symbol AVR, which closed at $4.98 per share on December 12, 2025.
Anteris Technologies Global Corp. disclosed that Stephen Denaro resigned from its Board of Directors and as a Class II director, effective December 13, 2025. The company states that his resignation is not due to any disagreement with management or with its operations, policies, or practices, suggesting no underlying dispute at the board level.
Denaro will remain closely involved with the organization as corporate secretary of Anteris Technologies Pty Ltd and as a member of the boards of that company and other Australian subsidiaries. This shifts the composition of the U.S. parent’s board while maintaining leadership continuity within Anteris’s Australian entities.
Anteris Technologies Global Corp. director Gregory S. Moss reported receiving two grants of restricted stock units tied to the company’s common stock. One grant covers 52,742 restricted stock units, each representing a right to receive one share of common stock.
These 52,742 units vest in three approximately equal annual installments on June 7, 2026, 2027 and 2028, subject to his continued service. A second grant of 13,821 restricted stock units also represents one share of common stock per unit and vests on the earlier of the first anniversary of the grant date and the next annual stockholders meeting, subject to continued service.
Anteris Technologies Global Corp. is registering 9,103,796 shares of common stock for resale by existing investors. The shares consist of 2,346,936 already-issued shares, 2,346,936 shares issuable upon exercise of common stock warrants, 2,079,962 shares underlying CHESS Depositary Interests (CDIs), and 2,329,962 shares issuable upon exercise of CDI warrants. These securities were issued in an October–November 2025 private placement. Anteris will not receive proceeds from stockholder resales but could receive up to approximately $40.4 million if all related warrants are exercised at $7.50 per share for common stock warrants and A$11.50 per CDI for CDI warrants. As of September 30, 2025, 36,062,370 shares of common stock were outstanding. Anteris is a development-stage structural heart company focused on its DurAVR® transcatheter heart valve and the global PARADIGM pivotal trial in severe aortic stenosis; prior audited financials include an explanatory paragraph about substantial doubt regarding its ability to continue as a going concern.
Anteris Technologies Global Corp. reported that it has presented new clinical information on its DurAVR® Transcatheter Heart Valve (THV). The company issued an ASX announcement on November 16, 2025 (November 17, 2025 AEDT) and a press release on November 17, 2025 summarizing 30-day clinical outcomes in one hundred severe aortic stenosis patients with small aortic annuli treated with DurAVR THV. This information is being furnished to regulators rather than formally filed, meaning it is shared for transparency but does not carry the same legal status as filed financial statements.
FAQ
What is the current stock price of ANTERIS TECHNOLOGIES GLOBAL (AVR)?
What is the market cap of ANTERIS TECHNOLOGIES GLOBAL (AVR)?
